Ken Alltucker, USA TODAY Published 3:21 p.m. ET May 11, 2020 | Updated 4:25 p.m. ET May 11, 2020CLOSE Infectious disease expert Michael Osterholm talks about our lack of national plan and when we will have testing available. USA TODAYA high-profile infectious disease researcher warns COVID-19 is in the early stages of attacking the world,…
California is one of a handful of states where coronavirus cases and deaths are projected to rise faster than researchers expected, according to the latest calculations in a widely relied-upon model of the COVID-19 outbreak.Christopher Murray, director of the University of Washington’s Institute for Health Metrics and Evaluation, said Sunday on CBS’ “Face the Nation”…
News ReleaseTuesday, April 21, 2020 “Living document” expected to be updated often as new clinical data accrue. Colorized scanning electron micrograph of an apoptotic cell (green) infected with SARS-COV-2 virus particles (orange), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland.NIAID A panel of U.S. physicians,…
Robert F. Kennedy Jr. has rightly made “radical transparency” the motto of his Department of Health and Human Services. HHS even has a page by that name. I think it is a good motto, and I want to help Secretary Kennedy and Acting FDA Commissioner Kyle Diamantas deliver on it in food safety, with two citizen petitions
Published: October 30, 2026, 10:16 pm Several reports of children choking have led to an FDA warning against Once Upon A Time snacks. The warning covers all flavors, quantities, lots and dates of Once Upon A Farm Tractor Wheels Organic, Toddler Soft-Baked Bars. The FDA has received several reports that describe infants ages 1.5 to
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment